XASX
CYV
Market cap3mUSD
Jul 08, Last price
0.01AUD
1D
-7.14%
Jan 2017
-98.46%
Name
Opthea Ltd
Chart & Performance
P/E
—
P/S
493.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
36.25%
Rev. gr., 5y
-29.73%
Revenues
25k
-79.95%
Net income
-164m
L-25.63%
CFO
-159m
L-1.12%
Dividend
Oct 11, 20040.12 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating primarily out of Australia, Opthea Limited is a clinical-stage biopharmaceutical firm dedicated to developing and marketing treatments for ophthalmic conditions. Its therapeutic pipeline leverages a robust intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) such as VEGF-C and VEGF-D, along with VEGF Receptor-3. This scientific foundation aims to address disorders characterized by abnormal blood and lymphatic vessel formation and excessive vascular leakage. The company's flagship product, OPT 302, is currently undergoing clinical trials. This soluble form of VEGFR-3 is being explored as a groundbreaking treatment for both wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Notably, OPT 302 functions as a novel VEGF-C/D inhibitor, intended to be administered alongside existing VEGF-A inhibitors to combat wet AMD and various other retinal disorders. Initially incorporated in 1984 as Circadian Technologies Limited, the company officially adopted the name Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||